BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miller JJ, Gaiddon C, Storr T. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer. Chem Soc Rev 2020;49:6995-7014. [DOI: 10.1039/d0cs00163e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 De Azevedo J, Mourtada J, Bour C, Devignot V, Schultz P, Borel C, Pencreach E, Mellitzer G, Gaiddon C, Jung AC. The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. Cells 2022;11:2866. [DOI: 10.3390/cells11182866] [Reference Citation Analysis]
2 Zhao Q, Xiong S, Chen C, Zhu H, Xie X, Peng C, He G, Han B. Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity. Front Oncol 2022;12:972372. [DOI: 10.3389/fonc.2022.972372] [Reference Citation Analysis]
3 Miller JJ, Kwan K, Gaiddon C, Storr T. A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer. J Biol Inorg Chem 2022. [PMID: 35488931 DOI: 10.1007/s00775-022-01939-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tang Y, Yang X, Wang Q, Huang H, Wang Q, Jiang M, Yuan C, Huang Y, Chen Y. ING4 Promotes Stemness Enrichment of Human Renal Cell Carcinoma Cells Through Inhibiting DUSP4 Expression to Activate the p38 MAPK/type I IFN-Stimulated Gene Signaling Pathway. Front Pharmacol 2022;13:845097. [DOI: 10.3389/fphar.2022.845097] [Reference Citation Analysis]
5 Wu X, Lu Y, Qin X. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis. J Ethnopharmacol 2022;283:114690. [PMID: 34597653 DOI: 10.1016/j.jep.2021.114690] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
6 Ji H, Wang W, Li X, Han X, Zhang X, Wang J, Liu C, Huang L, Gao W. Natural Small Molecules Enabled Efficient Immunotherapy through Supramolecular Self-Assembly in P53-Mutated Colorectal Cancer. ACS Appl Mater Interfaces 2022;14:2464-77. [PMID: 35045602 DOI: 10.1021/acsami.1c16737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Deng Y, Li Y, Wang Y, Sun S, Ma S, Jia P, Li W, Wang K, Yan W. Efficient enantioselective synthesis of CF 2 H-containing dispiro[benzo[ b ]thiophene-oxindole-pyrrolidine]s via organocatalytic cycloaddition. Org Chem Front 2021;9:210-5. [DOI: 10.1039/d1qo01392k] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhao M, Tang Z, Wang Y, Ding J, Guo Y, Zhang N, Gao T. MIR-4507 Targets TP53 to Facilitate the Malignant Progression of Non-small-cell Lung Cancer. J Cancer 2021;12:6600-9. [PMID: 34659550 DOI: 10.7150/jca.60724] [Reference Citation Analysis]
9 Gaiddon C, Gross I, Meng X, Sidhoum M, Mellitzer G, Romain B, Delhorme JB, Venkatasamy A, Jung AC, Pfeffer M. Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer. Molecules 2021;26:5386. [PMID: 34500819 DOI: 10.3390/molecules26175386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Petronilho EC, Pedrote MM, Marques MA, Passos YM, Mota MF, Jakobus B, de Sousa GDS, Pereira da Costa F, Felix AL, Ferretti GDS, Almeida FP, Cordeiro Y, Vieira TCRG, de Oliveira GAP, Silva JL. Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands. Chem Sci 2021;12:7334-49. [PMID: 34163823 DOI: 10.1039/d1sc01739j] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Huang X, Wang M, Liu Y, Gui Y. Synthesis of RNA-based gene regulatory devices for redirecting cellular signaling events mediated by p53. Theranostics 2021;11:4688-98. [PMID: 33754021 DOI: 10.7150/thno.55856] [Reference Citation Analysis]
12 Huang X, Zhou Q, Wang M, Cao C, Ma Q, Ye J, Gui Y. A Light-Inducible Split-dCas9 System for Inhibiting the Progression of Bladder Cancer Cells by Activating p53 and E-cadherin. Front Mol Biosci 2020;7:627848. [PMID: 33469550 DOI: 10.3389/fmolb.2020.627848] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Soond SM, Savvateeva LV, Makarov VA, Gorokhovets NV, Townsend PA, Zamyatnin AA Jr. Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis. Cancers (Basel) 2020;12:E3476. [PMID: 33266503 DOI: 10.3390/cancers12113476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]